Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Targeted Collection of Plasmid DNA in Large and Growing Animal Muscles 6 Weeks after DNA Vaccination with and without Electroporation.

Dory D, Le Moigne V, Cariolet R, Béven V, Keranflec'h A, Jestin A.

J Immunol Res. 2015;2015:326825. doi: 10.1155/2015/326825.

2.

Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Leaman DP, Lee JH, Ward AB, Zwick MB.

J Virol. 2015 Jul;89(13):6725-45. doi: 10.1128/JVI.03738-14.

3.

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.

Riede O, Seifert K, Oswald D, Endmann A, Hock C, Winkler A, Salguero FJ, Schroff M, Croft SL, Juhls C.

Gene Ther. 2015 Aug;22(8):628-35. doi: 10.1038/gt.2015.35.

4.

Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.

Kines RC, Zarnitsyn V, Johnson TR, Pang YY, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, Schiller JT, Graham BS.

PLoS One. 2015 Mar 18;10(3):e0120797. doi: 10.1371/journal.pone.0120797.

5.

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.

Xu Y, Yuen PW, Lam JK.

Pharmaceutics. 2014 Jul 10;6(3):378-415. doi: 10.3390/pharmaceutics6030378.

6.

Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta).

Kumar BD, Kumar PU, Krishna TP, Kalyanasundaram S, Suresh P, Jagadeesan V, Hariharan S, Naidu AN, Krishnaswamy K, Rangarajan PN, Srinivasan VA, Reddy GS, Sesikeran B.

Indian J Med Res. 2013 Jun;137(6):1072-88.

7.

Clinical applications of DNA vaccines: current progress.

Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB.

Clin Infect Dis. 2011 Aug 1;53(3):296-302. doi: 10.1093/cid/cir334. Review.

8.

DNA vaccines: developing new strategies against cancer.

Fioretti D, Iurescia S, Fazio VM, Rinaldi M.

J Biomed Biotechnol. 2010;2010:174378. doi: 10.1155/2010/174378. Review.

9.

Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Williams JA, Carnes AE, Hodgson CP.

Biotechnol Adv. 2009 Jul-Aug;27(4):353-70. doi: 10.1016/j.biotechadv.2009.02.003. Review.

10.

Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts.

Sheets RL, Stein J, Bailer RT, Koup RA, Andrews C, Nason M, He B, Koo E, Trotter H, Duffy C, Manetz TS, Gomez P.

J Immunotoxicol. 2008 Jul;5(3):315-35. doi: 10.1080/15376510802312464.

11.

DNA vaccines: ready for prime time?

Kutzler MA, Weiner DB.

Nat Rev Genet. 2008 Oct;9(10):776-88. doi: 10.1038/nrg2432. Review.

12.

DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Dumonteil E.

J Biomed Biotechnol. 2007;2007(6):90520.

13.

Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.

Schepp-Berglind J, Luo M, Wang D, Wicker JA, Raja NU, Hoel BD, Holman DH, Barrett AD, Dong JY.

Clin Vaccine Immunol. 2007 Sep;14(9):1117-26.

14.

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israel ZR, Eldridge JH, Egan MA.

J Virol. 2007 May;81(10):5257-69.

15.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team..

J Infect Dis. 2006 Dec 15;194(12):1650-60.

Supplemental Content

Support Center